abstract: In an attempt to maximize the quality of life of @entity3 @entity0 on prolonged total @entity4 ablation and to minimize side effects, we have devised a strategy of 'sequential @entity4 blockade'. Animal studies have demonstrated that the combination of the @entity6 inhibitor @entity5 and the antiandrogen @entity7 was as effective as a luteinizing hormone-releasing hormone analog and @entity7 in inhibiting the growth of the prostate. In a pilot trial, 10 potent @entity0 with clinical stage C and @entity3 were given the combination of @entity5 (5 mg b.i.d.) and @entity7 (125-250 mg t.i.d.). Eight of ten @entity0 remained potent. At 3 months the mean prostate-specific antigen level of all @entity0 was 3.8 ng/ml (34 ng/ml prior to therapy). In all patients serum @entity2 increased and those with the highest increase demonstrated @entity1 . The combination was easily tolerable and side effects were few. This treatment regime appears to offer the benefits of total @entity4 blockade, is less expensive and has fewer side effects. Further trials are warranted.

title: Treatment of @entity3 with the combination of @entity5 plus XXXX : early results.

answer: @entity7


abstract: In an attempt to maximize the quality of life of @entity3 @entity0 on prolonged total @entity4 ablation and to minimize side effects, we have devised a strategy of 'sequential @entity4 blockade'. Animal studies have demonstrated that the combination of the @entity6 inhibitor @entity5 and the antiandrogen @entity7 was as effective as a luteinizing hormone-releasing hormone analog and @entity7 in inhibiting the growth of the prostate. In a pilot trial, 10 potent @entity0 with clinical stage C and @entity3 were given the combination of @entity5 (5 mg b.i.d.) and @entity7 (125-250 mg t.i.d.). Eight of ten @entity0 remained potent. At 3 months the mean prostate-specific antigen level of all @entity0 was 3.8 ng/ml (34 ng/ml prior to therapy). In all patients serum @entity2 increased and those with the highest increase demonstrated @entity1 . The combination was easily tolerable and side effects were few. This treatment regime appears to offer the benefits of total @entity4 blockade, is less expensive and has fewer side effects. Further trials are warranted.

title: Treatment of XXXX with the combination of @entity5 plus @entity7 : early results.

answer: @entity3


abstract: In an attempt to maximize the quality of life of @entity3 @entity0 on prolonged total @entity4 ablation and to minimize side effects, we have devised a strategy of 'sequential @entity4 blockade'. Animal studies have demonstrated that the combination of the @entity6 inhibitor @entity5 and the antiandrogen @entity7 was as effective as a luteinizing hormone-releasing hormone analog and @entity7 in inhibiting the growth of the prostate. In a pilot trial, 10 potent @entity0 with clinical stage C and @entity3 were given the combination of @entity5 (5 mg b.i.d.) and @entity7 (125-250 mg t.i.d.). Eight of ten @entity0 remained potent. At 3 months the mean prostate-specific antigen level of all @entity0 was 3.8 ng/ml (34 ng/ml prior to therapy). In all patients serum @entity2 increased and those with the highest increase demonstrated @entity1 . The combination was easily tolerable and side effects were few. This treatment regime appears to offer the benefits of total @entity4 blockade, is less expensive and has fewer side effects. Further trials are warranted.

title: Treatment of @entity3 with the combination of XXXX plus @entity7 : early results.

answer: @entity5


abstract: @entity4 antagonists have revolutionized the treatment of @entity7 . Nevertheless, between 30 and 45% of @entity0 discontinue infliximab and other @entity4 antagonists over a 2- to 6-year period due to nonresponse, loss of response, or adverse events. Accordingly, the need for novel therapies grows each year. Recent studies have demonstrated the promise of new drugs with distinct modes of action for the treatment of @entity2 ( @entity2 ) and @entity1 ( @entity1 ). These include agents targeting leukocyte trafficking, therapies directed against IL-12/23 and Janus kinases (JAK), and antibodies against the classic inflammatory cytokine, @entity5 . The anti-a4-integrin antibody, natalizumab, was the first effective antitrafficking agent for @entity1 ; however, its use has been greatly limited by the risk of progressive multifocal @entity3 . Therefore, second-generation antitrafficking agents have focused on restricting leukocyte blockade to the intestine through mechanisms interfering with a4b7-integrin and its interaction with mucosal addressin cellular adhesion molecule 1. @entity6 is a cytokine central to the adaptive immune responses that characterize @entity7 . Ustekinumab, targeting the p40 subunit of IL-12 and @entity6 , and the oral JAK inhibitor @entity8 have proven to be effective in phase 2 trials in @entity1 and @entity2 , respectively. In addition, antibodies targeting the proinflammatory cytokine @entity5 are being studied in @entity1 . Each of the approaches described have promise as well as limitations, so it is likely that the search for novel agents in @entity7 will continue.    2014 S. Karger AG, Basel.

title: New Drugs on the Horizon for XXXX .

answer: @entity7


abstract: The clinical usefulness of pretreatment imaging techniques for predicting neck control in @entity0 with oropharyngeal or @entity3 (OHSCC) treated with chemoradiation remains unclear. In this prospective study, we investigated the role of pretreatment dynamic contrast-enhanced perfusion MR imaging (DCE-PWI), diffusion-weighted MR imaging (DWI), and @entity2 -positron emission tomography ( @entity2 PET)/CT derived imaging markers for the prediction of neck control in OHSCC @entity0 treated with chemoradiation. @entity0 with untreated OHSCC scheduled for chemoradiation between August, 2010 and July, 2012 were eligible for the study. Clinical variables and the following imaging parameters of metastatic neck lymph nodes were examined in relation to neck control: transfer constant, volume of blood plasma, and volume of extracellular extravascular space (Ve) on DCE-PWI; apparent diffusion coefficient (ADC) on DWI; maximum standardized uptake value, metabolic @entity1 volume, and total lesion glycolysis on @entity2 PET/CT. There were 69 @entity0 (37 with oropharynx SCC and 32 with hypopharynx SCC) with successful pretreatment DCE-PWI and DWI available for analysis. After a median follow-up of 31 months, 25 (36.2%) @entity0 had neck failure. Multivariate analysis identified hemoglobin level <14.3 g/dL (P=0.019), Ve <0.23 (P=0.040), and ADC >1.14*10-3 mm2/s (P=0.003) as independent prognostic factors for 3-year neck control. A prognostic scoring system was formulated by summing up the three significant predictors of neck control. @entity0 with scores of 2-3 had significantly poorer neck control and overall survival rates than @entity0 with scores of 0-1. We conclude that hemoglobin levels, Ve, and ADC are independent pretreatment prognostic factors for neck control in OHSCC treated with chemoradiation. Their combination may identify a subgroup of @entity0 at high risk of developing neck failure.

title: Clinical Utility of Multimodality Imaging with Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and @entity2 PET/CT for the Prediction of Neck Control in Oropharyngeal or XXXX Treated with Chemoradiation.

answer: @entity3


abstract: The clinical usefulness of pretreatment imaging techniques for predicting neck control in @entity0 with oropharyngeal or @entity3 (OHSCC) treated with chemoradiation remains unclear. In this prospective study, we investigated the role of pretreatment dynamic contrast-enhanced perfusion MR imaging (DCE-PWI), diffusion-weighted MR imaging (DWI), and @entity2 -positron emission tomography ( @entity2 PET)/CT derived imaging markers for the prediction of neck control in OHSCC @entity0 treated with chemoradiation. @entity0 with untreated OHSCC scheduled for chemoradiation between August, 2010 and July, 2012 were eligible for the study. Clinical variables and the following imaging parameters of metastatic neck lymph nodes were examined in relation to neck control: transfer constant, volume of blood plasma, and volume of extracellular extravascular space (Ve) on DCE-PWI; apparent diffusion coefficient (ADC) on DWI; maximum standardized uptake value, metabolic @entity1 volume, and total lesion glycolysis on @entity2 PET/CT. There were 69 @entity0 (37 with oropharynx SCC and 32 with hypopharynx SCC) with successful pretreatment DCE-PWI and DWI available for analysis. After a median follow-up of 31 months, 25 (36.2%) @entity0 had neck failure. Multivariate analysis identified hemoglobin level <14.3 g/dL (P=0.019), Ve <0.23 (P=0.040), and ADC >1.14*10-3 mm2/s (P=0.003) as independent prognostic factors for 3-year neck control. A prognostic scoring system was formulated by summing up the three significant predictors of neck control. @entity0 with scores of 2-3 had significantly poorer neck control and overall survival rates than @entity0 with scores of 0-1. We conclude that hemoglobin levels, Ve, and ADC are independent pretreatment prognostic factors for neck control in OHSCC treated with chemoradiation. Their combination may identify a subgroup of @entity0 at high risk of developing neck failure.

title: Clinical Utility of Multimodality Imaging with Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and XXXX PET/CT for the Prediction of Neck Control in Oropharyngeal or @entity3 Treated with Chemoradiation.

answer: @entity2


abstract: Although often viewed as a single disease, @entity1 more accurately represents a family of diseases with different precursor lesions. Conventional (tubular, tubulovillous and villous) @entity6 are the most common @entity9 occurring in the large intestine. They have @entity10 ( @entity10 ) mutations and arise from dysplastic aberrant crypt foci, initially as @entity2 . In @entity0 , @entity0 follows the traditional pathway (chromosomal instability pathway), resulting in CpG island methylator phenotype (CIMP)-negative, @entity3 ( @entity3 ), @entity7 and @entity8 wild-type @entity0 . Germline mutations in the @entity10 gene lead to @entity10 . Conventional @entity6 are also the precursors of @entity11 -associated microsatellite-instable ( @entity13 -high) @entity0 . Sessile serrated @entity12 (SSA/P) is the principal precursor lesion of the serrated pathway, in which @entity7 mutation can lead to @entity1 with @entity13 -high CIMP-high or @entity3 CIMP-high phenotype. SSA/Ps have been associated with synchronous and metachronous invasive @entity5 as well as so-called interval @entity4 . Serrated @entity10 is rare but most likely underdiagnosed. Affected individuals bear an increased but unspecified risk for the development of @entity1 ; close endoscopic surveillance is warranted. @entity6 ( @entity6 ) are much less common than the other serrated lesions. Cancers originating from @entity6 may show @entity8 mutation with a CIMP-high @entity3 phenotype.    2014 S. Karger AG, Basel.

title: Serrated and non-serrated precursor lesions of XXXX .

answer: @entity1


abstract: BACKGROUND: Effects of blood pressure reduction in @entity0 with grade 1 @entity4 are unclear. PURPOSE: To investigate whether pharmacologic blood pressure reduction prevents @entity3 and @entity5 in @entity0 with grade 1 @entity4 . DATA SOURCES: Trials included in the BPLTTC (Blood Pressure Lowering Treatment Trialists' Collaboration) and trials identified from a previous review and electronic database searches. STUDY SELECTION: @entity0 without @entity3 with blood pressures in the grade 1 @entity4 range (140 to 159/90 to 99 mm Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or control (placebo or less intensive regimen) blood pressure-lowering regimen. DATA EXTRACTION: Individual- @entity0 data from BPLTTC trials and aggregate data from other trials were extracted. Risk of bias was assessed for all trials. DATA SYNTHESIS: Individual- @entity0 data involved 10 comparisons from trials where most @entity0 had @entity1 , and aggregate data involved 3 comparisons from trials of @entity0 without @entity1 . The average blood pressure reduction was about 3.6/2.4 mm Hg. Over 5 years, odds ratios were 0.86 (95% CI, 0.74 to 1.01) for total @entity3 , 0.72 (CI, 0.55 to 0.94) for @entity2 , 0.91 (CI, 0.74 to 1.12) for coronary events, 0.80 (CI, 0.57 to 1.12) for @entity6 , 0.75 (CI, 0.57 to 0.98) for @entity3 , and 0.78 (CI, 0.67 to 0.92) for total @entity5 . Results were similar in secondary analyses. Withdrawal from treatment due to adverse effects was more common in the active groups. LIMITATION: Blood pressure reductions and numbers of events were small. CONCLUSION: Blood pressure-lowering therapy is likely to prevent @entity2 and @entity5 in @entity0 with uncomplicated grade 1 @entity4 . PRIMARY FUNDING SOURCE: Swedish Heart-Lung Foundation, Swedish Research Council, Australian Research Council, and National Health and Medical Research Council of Australia.

title: Effects of blood pressure reduction in mild XXXX : a systematic review and meta-analysis.

answer: @entity4


abstract: PURPOSE: The acute morbidity of doses of 64.8-75.6 Gy and preliminary observations of late complications and @entity1 response using 3-dimensional conformal radiation therapy in @entity3 are assessed. METHODS AND MATERIALS: 123 @entity0 (Stage A2-12, B1-17, B2-43, C-51) were irradiated to the prostate and seminal vesicles using a 3-dimensional conformal radiation therapy technique. The median follow-up time was 15.2 months. The minimum @entity1 dose was 64.8-66.6 Gy in 49 @entity0 , 70.2 Gy in 46, and 75.6 Gy in 28. @entity2 was scored according to the Radiation Therapy Oncology Group morbidity grading system. RESULTS: This technique of 3-dimensional conformal radiation therapy was well-tolerated with minimal acute morbidity. Only 32% of @entity0 had grade 2 or 3 acute morbidity requiring short-term medication for relief of urinary symptoms or @entity4 . Only one @entity0 (0.8%) has so far developed a severe (grade 4) late complication. Serum @entity5 concentrations normalized in 67% of @entity0 (64/96) within 1-14 months (median 4.5 months) after treatment and were progressively decreasing at last measurement in an additional 22% (21/96). Abnormal rising @entity5 levels were observed in 15 @entity0 , 11 of whom have already developed other evidence of relapsing disease. CONCLUSION: Acute @entity2 for the doses tested with this 3-dimensional conformal radiation therapy technique is reduced compared to traditional treatment techniques, and the initial @entity1 response as assessed by @entity5 measurement is highly encouraging with @entity5 levels returning to normal in the majority of @entity0 . Based on these results, a further increase of the dose to 81 Gy has been implemented in accordance with the schema of an ongoing Phase I dose-escalation study.

title: Three-dimensional conformal radiation therapy in locally advanced XXXX : preliminary results of a phase I dose-escalation study.

answer: @entity3


abstract: To discern if physical function test are better mortality predictors than muscle mass in elderly hospitalized @entity0 , we analyzed the prognostic value of muscle mass @entity3 and compared it with physical muscle function tests, including the six-minute walking test (6MWT) and hand grip strength. We included the ankle brachial index (ABI) to assess @entity1 , related to @entity2 due to hypoperfusion. We also analyzed the relationship of ABI with @entity3 , physical function tests and survival. We studied 310 hospitalized @entity0 older than 60 years. To assess nutritional status, we determined BMI, triceps skinfold and mid-arm muscle area; we performed a subjective nutritional assessment; and evaluated the degree of inflammatory stress. We assessed physical function by hand grip strength and 6MWT. We evaluated @entity1 by ABI. Forty-one @entity0 died during hospitalization; 269 were discharged and followed for a mean 808 days, reaching a mortality of 49%. Muscle @entity3 was frequent and was related to mortality, but the best predictors were physical function tests: inability to perform the 6MWT and low handgrip strength. Function tests were closely related to each other and correlated with nutritional data. Reduced ABI was related to impaired nutritional status, physical function tests and mortality.

title: Prognostic value of physical function tests: hand grip strength and six-minute walking test in elderly hospitalized XXXX .

answer: @entity0


abstract: UNASSIGNED: Background/Aim: We investigated the clinical efficacy of @entity3 ( @entity3 ) with AN69ST hemofilter (AN69ST- @entity3 ) in @entity0 with @entity2 . Materials and Methods: A prospective, multicenter, single-arm study was conducted. @entity0 with @entity1 and @entity6 defined by hyperlactemia were enrolled. The @entity0 were treated with @entity3 and in accordance with the Surviving Sepsis Campaign guidelines (SSCG). Results: Thirty-four @entity0 were enrolled. On ICU admission, the mean blood @entity4 level was 44,800    77,700 pg/ml, and the mean blood @entity5 level was 69.0    49.4 mg/dl. Both the mean blood @entity4 and @entity5 levels had significantly decreased to normal ranges after 72 h of AN69ST- @entity3 . Though the mean APACHE II score was 32.7    9.8, 28-day survival was 73.5%. Conclusion: The current study suggested that adding AN69ST- @entity3 to the treatments outlined in the SSCG might lead to good outcomes for @entity0 with @entity2 , probably via the removal of cytokines from the bloodstream.    2014 S. Karger AG, Basel.

title: Continuous Hemodiafiltration with a Cytokine-Adsorbing Hemofilter in @entity0 with XXXX : A Preliminary Report.

answer: @entity2


abstract: UNASSIGNED: Background/Aim: We investigated the clinical efficacy of @entity3 ( @entity3 ) with AN69ST hemofilter (AN69ST- @entity3 ) in @entity0 with @entity2 . Materials and Methods: A prospective, multicenter, single-arm study was conducted. @entity0 with @entity1 and @entity6 defined by hyperlactemia were enrolled. The @entity0 were treated with @entity3 and in accordance with the Surviving Sepsis Campaign guidelines (SSCG). Results: Thirty-four @entity0 were enrolled. On ICU admission, the mean blood @entity4 level was 44,800    77,700 pg/ml, and the mean blood @entity5 level was 69.0    49.4 mg/dl. Both the mean blood @entity4 and @entity5 levels had significantly decreased to normal ranges after 72 h of AN69ST- @entity3 . Though the mean APACHE II score was 32.7    9.8, 28-day survival was 73.5%. Conclusion: The current study suggested that adding AN69ST- @entity3 to the treatments outlined in the SSCG might lead to good outcomes for @entity0 with @entity2 , probably via the removal of cytokines from the bloodstream.    2014 S. Karger AG, Basel.

title: Continuous Hemodiafiltration with a Cytokine-Adsorbing Hemofilter in XXXX with @entity2 : A Preliminary Report.

answer: @entity0


abstract: OBJECTIVE: To examine the frequency and timing of @entity4 and its association with maternal serum @entity2 (MSAFP) levels. METHODS: Pregnancy outcomes were evaluated in 6927 predominantly middle-class @entity0 (83% white, 17% black) who had second-trimester MSAFP determinations performed in our laboratory. All cases of @entity5 , preexisting @entity4 , and @entity3 were excluded. RESULTS: The overall @entity4 rate was 13 per 1000 (n = 90). Black @entity0 had a higher @entity4 rate than white @entity0 (35.6 per 1000 versus 8.4 per 1000; P < .001). One hundred forty-eight @entity0 (2.1%) had an adjusted MSAFP multiples of the median (MoM) value of at least 2.5, which was not explained by @entity5 , @entity1 , or preexisting @entity4 . As the MSAFP increased, the @entity4 rate increased (MoM less than 2.0, 11 per 1000; MoM 2-2.49, 29 per 1000; MoM 2.5 or greater, 95 per 1000; P < .001). Despite the increased risk of @entity4 in the elevated MSAFP group, most @entity4 (84%) occurred in @entity0 with levels below 2.5 MoM. Furthermore, the timing of fetal loss was significantly different between the group less than 2.5 MoM and the group at or above 2.5 MoM. @entity4 occurred at or after 26 weeks in 45% of the @entity0 with normal MSAFP, compared with only 14% of @entity0 with high MSAFP (at least 2.5 MoM) (P = .023). CONCLUSIONS: @entity0 with unexplained elevations in MSAFP are at increased risk for fetal loss, with most of the losses occurring in the second trimester. Because many of these @entity4 occur at gestational ages when the neonatal survival is very low, it is unlikely that antepartum fetal surveillance aimed at early delivery would substantially increase fetal salvage.

title: Unexplained elevation in maternal serum XXXX and subsequent fetal loss.

answer: @entity2


abstract: (Full text is available at http://www.manu.edu.mk/prilozi). INTRODUCTION: Non-occlusive caecal @entity12 is a rare condition that has been described in association with a variety of clinical entities, generally due to a low-flow state, and has been reported to occur in association with @entity5 , open-heart surgery, certain drugs, and haemodialysis. The aim of this article is to describe the presentation, diagnosis and management of this unusual clinical problem. CASE PRESENTATION: We report on an 84-year-old female with known @entity5 presenting with right lower @entity7 , @entity11 and @entity8 . Although initial clinical findings were highly suggestive of @entity9 , CT revealed marked circumferential wall thickening of the caecum. Intraoperatively, caecal @entity1 was confirmed, while the appendix and the remainder of the intestine appeared normal. There was no evidence of major @entity6 or @entity10 . The right hemicolectomy was performed with ileo-transverse @entity4 . Histopathologic analysis demonstrated isolated transmural caecal @entity1 with marked infiltration of the caecal wall by numerous bacteria and neutrophils as a consequence of nonocclusive @entity13 . The @entity0 recovered completely and was discharged from the hospital on the tenth postoperative day without any surgical complications. CONCLUSION: Partial caecal @entity1 should be included in the differential diagnosis of acute right lower @entity3 , especially in elderly @entity0 with @entity5 . Key words: partial caecal @entity1 , @entity2 , @entity5 .

title: Partial caecal @entity1 - a rare cause of right-sided inferior @entity7 and XXXX .

answer: @entity11


abstract: (Full text is available at http://www.manu.edu.mk/prilozi). INTRODUCTION: Non-occlusive caecal @entity12 is a rare condition that has been described in association with a variety of clinical entities, generally due to a low-flow state, and has been reported to occur in association with @entity5 , open-heart surgery, certain drugs, and haemodialysis. The aim of this article is to describe the presentation, diagnosis and management of this unusual clinical problem. CASE PRESENTATION: We report on an 84-year-old female with known @entity5 presenting with right lower @entity7 , @entity11 and @entity8 . Although initial clinical findings were highly suggestive of @entity9 , CT revealed marked circumferential wall thickening of the caecum. Intraoperatively, caecal @entity1 was confirmed, while the appendix and the remainder of the intestine appeared normal. There was no evidence of major @entity6 or @entity10 . The right hemicolectomy was performed with ileo-transverse @entity4 . Histopathologic analysis demonstrated isolated transmural caecal @entity1 with marked infiltration of the caecal wall by numerous bacteria and neutrophils as a consequence of nonocclusive @entity13 . The @entity0 recovered completely and was discharged from the hospital on the tenth postoperative day without any surgical complications. CONCLUSION: Partial caecal @entity1 should be included in the differential diagnosis of acute right lower @entity3 , especially in elderly @entity0 with @entity5 . Key words: partial caecal @entity1 , @entity2 , @entity5 .

title: Partial caecal @entity1 - a rare cause of right-sided inferior XXXX and @entity11 .

answer: @entity7


abstract: (Full text is available at http://www.manu.edu.mk/prilozi). INTRODUCTION: Non-occlusive caecal @entity12 is a rare condition that has been described in association with a variety of clinical entities, generally due to a low-flow state, and has been reported to occur in association with @entity5 , open-heart surgery, certain drugs, and haemodialysis. The aim of this article is to describe the presentation, diagnosis and management of this unusual clinical problem. CASE PRESENTATION: We report on an 84-year-old female with known @entity5 presenting with right lower @entity7 , @entity11 and @entity8 . Although initial clinical findings were highly suggestive of @entity9 , CT revealed marked circumferential wall thickening of the caecum. Intraoperatively, caecal @entity1 was confirmed, while the appendix and the remainder of the intestine appeared normal. There was no evidence of major @entity6 or @entity10 . The right hemicolectomy was performed with ileo-transverse @entity4 . Histopathologic analysis demonstrated isolated transmural caecal @entity1 with marked infiltration of the caecal wall by numerous bacteria and neutrophils as a consequence of nonocclusive @entity13 . The @entity0 recovered completely and was discharged from the hospital on the tenth postoperative day without any surgical complications. CONCLUSION: Partial caecal @entity1 should be included in the differential diagnosis of acute right lower @entity3 , especially in elderly @entity0 with @entity5 . Key words: partial caecal @entity1 , @entity2 , @entity5 .

title: Partial caecal XXXX - a rare cause of right-sided inferior @entity7 and @entity11 .

answer: @entity1


abstract: OBJECTIVE: The @entity5 ( @entity5 ) has been largely ignored by physicians due to a lack of adequate data about the importance of @entity5 in @entity0 with @entity7 ( @entity7 ). We aimed to assess whether @entity5 dilatation develops in @entity0 with @entity7 and to demonstrate its relation with global myocardial function of the right ventricle (RV). METHODS: In this cross-sectional study, 45 healthy subjects and 95 @entity7 @entity0 exhibiting @entity9 on echocardiographic examination (EF <45%) secondary to @entity2 (n=56) or @entity8 ( @entity6 ) (n=39) were enrolled. @entity0 with severe @entity1 were excluded. @entity5 was measured by echocardiography from the posterior atrioventricular groove in the apical four-chamber view. The RV myocardial performance index (MPI), which reflects both systolic and diastolic function of the ventricle, was detected using tissue Doppler imaging, and @entity0 with an RV MPI >0.55 were defined as having @entity4 . ANOVA, Kruskal-Wallis, Pearson's correlation, and multivariate logistic regression analyses were used for the statistical analysis. RESULTS: The @entity5 and RV MPI values were significantly greater both in @entity0 with @entity2 and idiopathic @entity6 than in controls (8.79  1.7 mm and 8.33  2.1 mm vs. 5.74  0.6 mm, and 0.64  0.07 and 0.62  0.08 vs. 0.43  0.02; p<0.001 for both, respectively). For the prediction of @entity7 @entity0 with @entity3 , the cut-off value for the diameter of the @entity5 was 7.35 mm, with a sensitivity of 83% and a specificity of 79%. CONCLUSION: The @entity5 diameter can be used as a novel echocardiographic marker that provides information about @entity3 in @entity0 with @entity7 .

title: XXXX is a sign of impaired right ventricular function in @entity0 with @entity7 .

answer: @entity6


abstract: OBJECTIVE: The @entity5 ( @entity5 ) has been largely ignored by physicians due to a lack of adequate data about the importance of @entity5 in @entity0 with @entity7 ( @entity7 ). We aimed to assess whether @entity5 dilatation develops in @entity0 with @entity7 and to demonstrate its relation with global myocardial function of the right ventricle (RV). METHODS: In this cross-sectional study, 45 healthy subjects and 95 @entity7 @entity0 exhibiting @entity9 on echocardiographic examination (EF <45%) secondary to @entity2 (n=56) or @entity8 ( @entity6 ) (n=39) were enrolled. @entity0 with severe @entity1 were excluded. @entity5 was measured by echocardiography from the posterior atrioventricular groove in the apical four-chamber view. The RV myocardial performance index (MPI), which reflects both systolic and diastolic function of the ventricle, was detected using tissue Doppler imaging, and @entity0 with an RV MPI >0.55 were defined as having @entity4 . ANOVA, Kruskal-Wallis, Pearson's correlation, and multivariate logistic regression analyses were used for the statistical analysis. RESULTS: The @entity5 and RV MPI values were significantly greater both in @entity0 with @entity2 and idiopathic @entity6 than in controls (8.79  1.7 mm and 8.33  2.1 mm vs. 5.74  0.6 mm, and 0.64  0.07 and 0.62  0.08 vs. 0.43  0.02; p<0.001 for both, respectively). For the prediction of @entity7 @entity0 with @entity3 , the cut-off value for the diameter of the @entity5 was 7.35 mm, with a sensitivity of 83% and a specificity of 79%. CONCLUSION: The @entity5 diameter can be used as a novel echocardiographic marker that provides information about @entity3 in @entity0 with @entity7 .

title: @entity6 is a sign of impaired right ventricular function in @entity0 with XXXX .

answer: @entity7


abstract: OBJECTIVE: The @entity5 ( @entity5 ) has been largely ignored by physicians due to a lack of adequate data about the importance of @entity5 in @entity0 with @entity7 ( @entity7 ). We aimed to assess whether @entity5 dilatation develops in @entity0 with @entity7 and to demonstrate its relation with global myocardial function of the right ventricle (RV). METHODS: In this cross-sectional study, 45 healthy subjects and 95 @entity7 @entity0 exhibiting @entity9 on echocardiographic examination (EF <45%) secondary to @entity2 (n=56) or @entity8 ( @entity6 ) (n=39) were enrolled. @entity0 with severe @entity1 were excluded. @entity5 was measured by echocardiography from the posterior atrioventricular groove in the apical four-chamber view. The RV myocardial performance index (MPI), which reflects both systolic and diastolic function of the ventricle, was detected using tissue Doppler imaging, and @entity0 with an RV MPI >0.55 were defined as having @entity4 . ANOVA, Kruskal-Wallis, Pearson's correlation, and multivariate logistic regression analyses were used for the statistical analysis. RESULTS: The @entity5 and RV MPI values were significantly greater both in @entity0 with @entity2 and idiopathic @entity6 than in controls (8.79  1.7 mm and 8.33  2.1 mm vs. 5.74  0.6 mm, and 0.64  0.07 and 0.62  0.08 vs. 0.43  0.02; p<0.001 for both, respectively). For the prediction of @entity7 @entity0 with @entity3 , the cut-off value for the diameter of the @entity5 was 7.35 mm, with a sensitivity of 83% and a specificity of 79%. CONCLUSION: The @entity5 diameter can be used as a novel echocardiographic marker that provides information about @entity3 in @entity0 with @entity7 .

title: @entity6 is a sign of impaired right ventricular function in XXXX with @entity7 .

answer: @entity0


abstract: OBJECTIVE: Measurement of @entity2 ( @entity2 ) was used to investigate the occurrence of feto-maternal @entity3 in @entity0 undergoing medical abortion. DESIGN: Three groups of @entity0 with @entity6 of 56 or less days were studied. A control and a @entity5 group had two blood samples taken 48 h apart. @entity0 undergoing medical abortion with gemeprost had two blood samples taken 24 h apart. SETTING: Medical Termination Unit, Simpson Memorial Maternity Pavilion, Edinburgh. SUBJECTS: Three hundred and thirty-five @entity0 requesting abortion. INTERVENTIONS: Blood samples taken at 24 h or 48 h apart. MEASUREMENTS AND MAIN RESULTS: The rise in concentration of @entity2 in plasma was much higher (P = 0.01) in the two groups of @entity0 in whom abortion was induced by gemeprost or @entity5 than in control @entity0 . Whereas only 5% of @entity0 in the control group had a significant rise in @entity2 , 27% and 33% of @entity0 in the @entity5 and gemeprost groups, respectively, had a rise in @entity2 level which exceeded the 95th centile (> or = 38%). The concentration of hCG rose by 48 h in both control and @entity5 groups. @entity4 remained unchanged, and @entity1 decreased (P < 0.02) in the @entity5 group. By 24 h, there was a significant fall in the concentrations of hCG, @entity4 and @entity1 in the group who had aborted after being given gemeprost. CONCLUSIONS: Anti-D prophylaxis must be administered to rhesus negative @entity0 to avoid rhesus iso-immunisation.

title: Changes in the concentration of XXXX and placental hormones following two methods of medical abortion in early pregnancy.

answer: @entity2


abstract: A 27-year-old @entity0 in late pregnancy presented to the department of obstetrics with crampy @entity3 located in the right flank, 3   years after a laparoscopic Roux-en-Y gastric bypass. Clinical investigation showed tenderness on palpation in the upper abdomen without signs of @entity2 . The cardiotocogram and blood tests were normal. The ultrasound showed a @entity5 on the right side, and a pigtail catheter was inserted. The abdominal symptoms did not abate and the abdominal surgeon was consulted 36   hours after admission. Diagnostic laparoscopy was performed promptly because of high suspicion of @entity4 ( @entity4 ). Laparoscopy showed @entity4 at the mesojejunal intermesenteric defect with a herniated common channel and @entity6 of the @entity1 . Conversion to open reduction and complete closure with non-absorbable interrupted sutures was performed. Small bowel resection was avoided. The @entity0 was discharged 10   days after the operation and a healthy @entity0 was born 4   weeks later.

title: Internal XXXX in late pregnancy after laparoscopic Roux-en-Y gastric bypass.

answer: @entity4


abstract: A study has been made of the susceptibility of recombinant constructs of reverse transcriptase (RT) and ribonuclease H (RNase H) from @entity3 ) to digestion by the @entity3 protease. At neutral pH, the protease attacks a single peptide bond, @entity1 440-Tyr441, in one of the protomers of the folded, active RT/RNase H ( @entity7 / @entity7 ) homodimer to give a stable, active heterodimer ( @entity7 / @entity5 ) that is resistant to further hydrolysis (Chattopadhyay, D., et al., 1992, J. Biol. Chem. 267, 14227-14232). The @entity2 -terminal @entity6 fragment released in the process, however, is rapidly degraded by the protease by cleavage at Tyr483-Leu484 and Tyr532-Leu533. In marked contrast to this @entity6 segment, both @entity7 / @entity5 and a folded RNase H construct are stable to breakdown by the protease at neutral pH. It is only at pH values around 4 that these latter proteins appear to unfold and, under these conditions, the heterodimer undergoes extensive proteolysis. RNase H is also hydrolyzed at low pH, but cleavage takes place primarily at @entity4 436-Ala437 and at @entity1 440-Tyr441, and only much more slowly at residues 483, 494, and 532. This observation can be reconciled by inspection of crystallographic models of RNase H, which show that residues 483, 494, and 532 are relatively inaccessible in comparison to @entity4 436 and @entity1 440. Our results fit a model in which the @entity7 / @entity7 homodimer exists in a conformation that mirrors that of the heterodimer, but with a @entity6 segment on one of the protomers that is structurally disordered to the extent that all of its potential @entity0 protease cleavage sites are accessible for hydrolysis.

title: XXXX reverse transcriptase and ribonuclease H as substrates of the viral protease.

answer: @entity3


abstract: 1. The present study was undertaken to determine the mechanism of action of @entity18 ( @entity18 )-induced contraction of the @entity2 isolated @entity1 . 2. @entity18 (1 nM-0.3 microM) produces a concentration-dependent contraction of @entity2 @entity1 with an EC50 of approximately 25 nM. The combination of the peptidoleukotriene receptor antagonist, SK_F 104353 (10 microM) and the H1- @entity0 receptor antagonist, @entity14 (10 microM), which abolishes antigen-induced contraction in @entity2 @entity1 , was without effect on @entity18 concentration-response curves. Furthermore, the @entity19 antagonist, @entity12 , (1 or 10 microM) did not inhibit ET-induced contraction. 3. @entity18 (0.3 microM) did not stimulate @entity0 or immunoreactive peptidoleukotriene release from @entity2 isolated @entity1 . 4. The release of various prostanoids from @entity2 @entity1 was increased significantly by @entity18 (0.3 microM); the profile of release was @entity4 (PGD2) = @entity3 = @entity15 (PGI2 metabolite) > @entity13 = PGF2 alpha > 9 alpha, 11 beta PGF2 (PGD2 metabolite). @entity18 -induced release of @entity6 , which was about 30% of that elicited by antigen in sensitized tissues, was not affected by epithelium removal and was observed in tissues from which the smooth muscle had been removed. Previous studies in our laboratory indicated that @entity8 potentiated contraction produced by high concentrations of @entity18 , whereas a @entity5 receptor antagonist was without appreciable effect on @entity18 concentration-response curves. 5. Pretreatment of tissues for 1 h with @entity7 (10 microM), which depletes different sensory neurones, produced a small, but significant, inhibitory effect on @entity18 concentration-response curves in the presence but not the absence of the epithelium. The combination of the NK1 @entity10 receptor antagonist,CP-96,345 (0.1 microM), and the @entity16 @entity10 receptor antagonist, @entity17 (0.1 microM), was without effect on ET-l concentration-response curves but substantially antagonized @entity7 -induced contraction.6. The present data suggest that in @entity2 isolated @entity1 , ET- 1 produces contraction predominantly via a direct mechanism: there is no significant contribution of the release of @entity0 , @entity9 , @entity11 , or @entity10 (acting on NK1 or @entity16 receptors). Although @entity18 evokes the release of an array of @entity6 from the @entity1 they do not appear to have a major influence on the contractile response.

title: Relative contributions of direct and indirect mechanisms mediating endothelin-induced contraction of XXXX @entity1 .

answer: @entity2


abstract: 1. The present study was undertaken to determine the mechanism of action of @entity18 ( @entity18 )-induced contraction of the @entity2 isolated @entity1 . 2. @entity18 (1 nM-0.3 microM) produces a concentration-dependent contraction of @entity2 @entity1 with an EC50 of approximately 25 nM. The combination of the peptidoleukotriene receptor antagonist, SK_F 104353 (10 microM) and the H1- @entity0 receptor antagonist, @entity14 (10 microM), which abolishes antigen-induced contraction in @entity2 @entity1 , was without effect on @entity18 concentration-response curves. Furthermore, the @entity19 antagonist, @entity12 , (1 or 10 microM) did not inhibit ET-induced contraction. 3. @entity18 (0.3 microM) did not stimulate @entity0 or immunoreactive peptidoleukotriene release from @entity2 isolated @entity1 . 4. The release of various prostanoids from @entity2 @entity1 was increased significantly by @entity18 (0.3 microM); the profile of release was @entity4 (PGD2) = @entity3 = @entity15 (PGI2 metabolite) > @entity13 = PGF2 alpha > 9 alpha, 11 beta PGF2 (PGD2 metabolite). @entity18 -induced release of @entity6 , which was about 30% of that elicited by antigen in sensitized tissues, was not affected by epithelium removal and was observed in tissues from which the smooth muscle had been removed. Previous studies in our laboratory indicated that @entity8 potentiated contraction produced by high concentrations of @entity18 , whereas a @entity5 receptor antagonist was without appreciable effect on @entity18 concentration-response curves. 5. Pretreatment of tissues for 1 h with @entity7 (10 microM), which depletes different sensory neurones, produced a small, but significant, inhibitory effect on @entity18 concentration-response curves in the presence but not the absence of the epithelium. The combination of the NK1 @entity10 receptor antagonist,CP-96,345 (0.1 microM), and the @entity16 @entity10 receptor antagonist, @entity17 (0.1 microM), was without effect on ET-l concentration-response curves but substantially antagonized @entity7 -induced contraction.6. The present data suggest that in @entity2 isolated @entity1 , ET- 1 produces contraction predominantly via a direct mechanism: there is no significant contribution of the release of @entity0 , @entity9 , @entity11 , or @entity10 (acting on NK1 or @entity16 receptors). Although @entity18 evokes the release of an array of @entity6 from the @entity1 they do not appear to have a major influence on the contractile response.

title: Relative contributions of direct and indirect mechanisms mediating endothelin-induced contraction of @entity2 XXXX .

answer: @entity1


abstract: BACKGROUND: @entity3 ( @entity3 ) is a useful @entity1 marker for @entity2 and @entity6 . Recently, elevations of serum @entity3 were reported in @entity0 with other @entity1 , especially @entity5 . Two distinct @entity1 morphologies, hepatoid and clear cell, have been correlated with @entity3 production. METHODS: Two @entity0 with @entity3 -producing @entity5 were evaluated with immunohistochemical, ultrastructural, and biochemical studies. RESULTS: In @entity0 1, the primary and metastatic @entity4 consisted homogeneously of @entity4 with clear cytoplasm. In @entity0 2, the @entity1 was composed of three different areas: @entity4 with clear cytoplasm, @entity1 cartilage, and so-called @entity4 . The morphologic characteristics of @entity4 with clear cytoplasm were similar to those of the developing gut epithelium at the stage of 2-4 months' gestation. The elution patterns of the serum @entity3 on lectin-affinity sepharose column study also suggested a correlation with fetal gut differentiation. CONCLUSIONS: @entity3 -producing clear cell @entity5 are differentiated into fetal intestine. One @entity0 also had hepatocytic and cartilaginous differentiation, indicative of a blastomatous characteristic of the @entity1 . These @entity1 arose in association with intestinal metaplasia.

title: @entity3 -producing XXXX with enteroblastic differentiation.

answer: @entity5


abstract: BACKGROUND: @entity3 ( @entity3 ) is a useful @entity1 marker for @entity2 and @entity6 . Recently, elevations of serum @entity3 were reported in @entity0 with other @entity1 , especially @entity5 . Two distinct @entity1 morphologies, hepatoid and clear cell, have been correlated with @entity3 production. METHODS: Two @entity0 with @entity3 -producing @entity5 were evaluated with immunohistochemical, ultrastructural, and biochemical studies. RESULTS: In @entity0 1, the primary and metastatic @entity4 consisted homogeneously of @entity4 with clear cytoplasm. In @entity0 2, the @entity1 was composed of three different areas: @entity4 with clear cytoplasm, @entity1 cartilage, and so-called @entity4 . The morphologic characteristics of @entity4 with clear cytoplasm were similar to those of the developing gut epithelium at the stage of 2-4 months' gestation. The elution patterns of the serum @entity3 on lectin-affinity sepharose column study also suggested a correlation with fetal gut differentiation. CONCLUSIONS: @entity3 -producing clear cell @entity5 are differentiated into fetal intestine. One @entity0 also had hepatocytic and cartilaginous differentiation, indicative of a blastomatous characteristic of the @entity1 . These @entity1 arose in association with intestinal metaplasia.

title: XXXX -producing @entity5 with enteroblastic differentiation.

answer: @entity3


abstract: PURPOSE: To develop @entity1 -induced @entity4 in the @entity0 with reproducible and quantifiable @entity6 suitable for examining pathogenesis and therapeutic intervention for @entity6 in @entity4 ( @entity4 ) and other vasculopathologies. METHODS: One-week-old C57BL/6J @entity0 were exposed to 75% @entity1 for 5 days and then to room air. A novel fluorescein-dextran perfusion method has been developed to assess the vascular pattern. The proliferative neovascular response was quantified by counting the nuclei of new vessels extending from the retina into the vitreous in 6 microns sagittal cross-sections. @entity7 were also stained for @entity8 ( @entity8 ). RESULTS: @entity3 -dextran angiography delineated the entire vascular pattern, including neovascular tufts in flat-mounted retinas. @entity2 -induced @entity5 occurred at the junction between the vascularized and avascular retina in the mid-periphery. @entity6 occurred in all the pups between postnatal day 17 and postnatal day 21. There was a mean of 89 neovascular nuclei per cross-section of 9 eyes in @entity2 compared to less than 1 nucleus per cross-section of 8 eyes in the normoxia control (P < 0.0001). Proliferative vessels were not associated with @entity8 -positive astrocyte processes. CONCLUSIONS: The authors have described a reproducible and quantifiable @entity0 model of @entity1 -induced @entity6 that should prove useful for the study of pathogenesis of @entity6 as well as for the study of medical intervention for @entity4 and other @entity4 .

title: XXXX -induced @entity4 in the @entity0 .

answer: @entity1


abstract: PURPOSE: To develop @entity1 -induced @entity4 in the @entity0 with reproducible and quantifiable @entity6 suitable for examining pathogenesis and therapeutic intervention for @entity6 in @entity4 ( @entity4 ) and other vasculopathologies. METHODS: One-week-old C57BL/6J @entity0 were exposed to 75% @entity1 for 5 days and then to room air. A novel fluorescein-dextran perfusion method has been developed to assess the vascular pattern. The proliferative neovascular response was quantified by counting the nuclei of new vessels extending from the retina into the vitreous in 6 microns sagittal cross-sections. @entity7 were also stained for @entity8 ( @entity8 ). RESULTS: @entity3 -dextran angiography delineated the entire vascular pattern, including neovascular tufts in flat-mounted retinas. @entity2 -induced @entity5 occurred at the junction between the vascularized and avascular retina in the mid-periphery. @entity6 occurred in all the pups between postnatal day 17 and postnatal day 21. There was a mean of 89 neovascular nuclei per cross-section of 9 eyes in @entity2 compared to less than 1 nucleus per cross-section of 8 eyes in the normoxia control (P < 0.0001). Proliferative vessels were not associated with @entity8 -positive astrocyte processes. CONCLUSIONS: The authors have described a reproducible and quantifiable @entity0 model of @entity1 -induced @entity6 that should prove useful for the study of pathogenesis of @entity6 as well as for the study of medical intervention for @entity4 and other @entity4 .

title: @entity1 -induced XXXX in the @entity0 .

answer: @entity4


abstract: PURPOSE: To develop @entity1 -induced @entity4 in the @entity0 with reproducible and quantifiable @entity6 suitable for examining pathogenesis and therapeutic intervention for @entity6 in @entity4 ( @entity4 ) and other vasculopathologies. METHODS: One-week-old C57BL/6J @entity0 were exposed to 75% @entity1 for 5 days and then to room air. A novel fluorescein-dextran perfusion method has been developed to assess the vascular pattern. The proliferative neovascular response was quantified by counting the nuclei of new vessels extending from the retina into the vitreous in 6 microns sagittal cross-sections. @entity7 were also stained for @entity8 ( @entity8 ). RESULTS: @entity3 -dextran angiography delineated the entire vascular pattern, including neovascular tufts in flat-mounted retinas. @entity2 -induced @entity5 occurred at the junction between the vascularized and avascular retina in the mid-periphery. @entity6 occurred in all the pups between postnatal day 17 and postnatal day 21. There was a mean of 89 neovascular nuclei per cross-section of 9 eyes in @entity2 compared to less than 1 nucleus per cross-section of 8 eyes in the normoxia control (P < 0.0001). Proliferative vessels were not associated with @entity8 -positive astrocyte processes. CONCLUSIONS: The authors have described a reproducible and quantifiable @entity0 model of @entity1 -induced @entity6 that should prove useful for the study of pathogenesis of @entity6 as well as for the study of medical intervention for @entity4 and other @entity4 .

title: @entity1 -induced @entity4 in the XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity6 caused by @entity4 worms is endemic to tropical regions where it is the most common cause of @entity1 . However, the intermediate @entity5 hosts, Bulinus truncatus, have been described in Portugal, Spain, Sardinia, and Corsica. @entity4 has long remained exotic to Europe, however, an outbreak of @entity6 in Corsica started in 2011 with B. truncatus as the primary intermediate host. We describe the case of a 12-year-old French @entity0 presenting @entity1 and @entity3 who was diagnosed with @entity6 . Urine examination confirmed the presence of viable parasitic ova. He also had a positive serology. Since there was no history of travel to a @entity2 endemic region, the probable area of contamination was identified as the south of Corsica where the family had spent their summer holidays 7 months earlier. Two other family members had a positive serology without ova excretion in urine. The @entity0 were treated with praziquantel. In light of these recent locally acquired cases in France, @entity2 should be considered in the differential diagnosis of @entity1 , especially in @entity0 who have recently visited Corsica.

title: An unusual case of XXXX in a French family returning from Corsica.

answer: @entity1


abstract: OBJECTIVE: In adults with arterial @entity2 , measuring arterial stiffness by pulse wave velocity ( @entity3 ) can determine the extent of cardiovascular subclinical organ damage. @entity3 has independent predictive value for cardiovascular events, but there are currently no recommendations for measuring @entity3 in @entity0 . In addition, central systolic blood pressure (cSBP) strongly reflects vascular changes. The aim of this study was to establish percentiles for cSBP and @entity3 in @entity0 and adolescents to evaluate and classify altered vascular function in youths. METHODS AND RESULTS: We measured @entity3 and cSBP with an oscillometric device with inbuilt ARCSolver-algorithm (estimated by using the brachial waveform) and calculated smoothed reference percentiles for 1445 @entity0 and young adults (49.5% female; 13.41      2.80 years, range 8-22 years; @entity3 4.67      0.34  m/s; cSBP 100.7      8.9  mmHg) using the LMS-method based on age and height. @entity3 and cSBP increased with age and height, but slightly differently for @entity0 and @entity0 , possibly reflecting different growth patterns. Between 8 and 21 years, @entity3 increased from 4.29      0.32 to 4.98      0.33  m/s in @entity0 and from 4.27      0.18 to 5.22      0.46  m/s in @entity0 . While @entity0 showed a minor increase in cSBP (91.2      7.5 to 109.1      8.6  mmHg), the cSBP in @entity0 ranged from 90.0      5.8 to 110.5      9.6  mmHg with a more pronounced increase between 14 and 17 years. CONCLUSION: These percentiles for @entity3 and cSBP can help define arterial stiffness in youths and contribute to risk stratification for @entity1 . For example, in @entity0 with @entity4 or isolated systolic @entity2 , @entity3 and cSBP can provide additional information about the function of the vascular system, thereby strengthening intervention strategies.

title: Percentiles for central blood pressure and pulse wave velocity in XXXX and adolescents recorded with an oscillometric device.

answer: @entity0


abstract: Objective. Immune processes play a significant role in @entity4 plaque progression. Regulatory T cells and T helpers 17 were shown to possess anti- and pro-atherogenic activity, respectively. We aimed to investigate the balance of circulating Treg and Th17 in stable @entity5 @entity0 with different stages of @entity2 . Methods. Treg, Th17 and Th1 cell frequencies were studied in 117 @entity0 via direct immunofluorescence staining and flow cytometry. Group 1 had intact coronary arteries. Group 2 and Group 3 had undergone previous coronary stenting; in Group 2 no @entity2 was found, in Group 3 @entity0 had disease progression in non-invaded coronary arteries. Group 4 had severe @entity2 . Results. The frequencies of @entity1 +CD25highCD127low, @entity1 +foxp3+, and @entity1 +IL10  +  T cells were decreased, and @entity1 +IL17  +  T cells frequencies were increased in group 4 vs. 1. Treg/Th17 ratios were declined in groups 3 and 4 vs. groups 1 and 2. @entity3 level was lower while hsCRP and sCD25 levels were higher in group 4 vs. 1. Conclusion. We assume that the imbalance in pro- and anti-inflammatory/atherogenic lymphocyte subpopulations is associated with @entity4 progression.

title: Treg/Th17 balance in stable CAD @entity0 with different stages of XXXX .

answer: @entity2


abstract: Objective. Immune processes play a significant role in @entity4 plaque progression. Regulatory T cells and T helpers 17 were shown to possess anti- and pro-atherogenic activity, respectively. We aimed to investigate the balance of circulating Treg and Th17 in stable @entity5 @entity0 with different stages of @entity2 . Methods. Treg, Th17 and Th1 cell frequencies were studied in 117 @entity0 via direct immunofluorescence staining and flow cytometry. Group 1 had intact coronary arteries. Group 2 and Group 3 had undergone previous coronary stenting; in Group 2 no @entity2 was found, in Group 3 @entity0 had disease progression in non-invaded coronary arteries. Group 4 had severe @entity2 . Results. The frequencies of @entity1 +CD25highCD127low, @entity1 +foxp3+, and @entity1 +IL10  +  T cells were decreased, and @entity1 +IL17  +  T cells frequencies were increased in group 4 vs. 1. Treg/Th17 ratios were declined in groups 3 and 4 vs. groups 1 and 2. @entity3 level was lower while hsCRP and sCD25 levels were higher in group 4 vs. 1. Conclusion. We assume that the imbalance in pro- and anti-inflammatory/atherogenic lymphocyte subpopulations is associated with @entity4 progression.

title: Treg/Th17 balance in stable CAD XXXX with different stages of @entity2 .

answer: @entity0


abstract: A new @entity1 biosensor was constructed using @entity2 (Fc) induced electro-activated uricase ( @entity6 ) deposited within @entity5 (Naf) on glassy @entity3 electrode (GCE). Electro-activation of @entity6 was successfully achieved by cyclic voltammetry through the electrostatic interaction of Fc with Trp residues within the hydrophobic pockets in @entity6 . The Naf/ @entity6 /Fc composite was characterised by AFM, FTIR and EDX to ensure proper immobilisation. The interaction of Fc with the enzyme was analysed by Trp fluorescence spectroscopy and the a-helicity of the protein was measured by CD spectropolarimetry. The charge transfer resistance (Rct), calculated from electrochemical impedance spectroscopy, for the modified sensor was lowered (1.39k   ) and the enzyme efficiency was enhanced by more than two fold as a result of Fc incorporation. Cyclic voltammetry, differential pulse voltammetry and amperometry all demonstrated the excellent response of the Naf/ @entity6 /Fc/GCE biosensor to @entity1 . The sensor system generated a linear response over a range of 500nM to 600 M UA, with a sensitivity and limit of detection of 1.78 A M(-1) and 230nM, respectively. The heterogeneous rate constant (ks) for UA oxidation was much higher for Naf/ @entity6 /Fc/GCE (1.0*10(-4)cms(-1)) than for @entity4 / @entity6 /GCE (8.2*10(-5)cms(-1)). Real samples, i.e. @entity0 blood, were tested for serum UA and the sensor yielded accurate results at a 95% confidence limit.

title: A novel third generation @entity1 biosensor using uricase electro-activated with XXXX on a @entity5 coated glassy @entity3 electrode.

answer: @entity2


abstract: A new @entity1 biosensor was constructed using @entity2 (Fc) induced electro-activated uricase ( @entity6 ) deposited within @entity5 (Naf) on glassy @entity3 electrode (GCE). Electro-activation of @entity6 was successfully achieved by cyclic voltammetry through the electrostatic interaction of Fc with Trp residues within the hydrophobic pockets in @entity6 . The Naf/ @entity6 /Fc composite was characterised by AFM, FTIR and EDX to ensure proper immobilisation. The interaction of Fc with the enzyme was analysed by Trp fluorescence spectroscopy and the a-helicity of the protein was measured by CD spectropolarimetry. The charge transfer resistance (Rct), calculated from electrochemical impedance spectroscopy, for the modified sensor was lowered (1.39k   ) and the enzyme efficiency was enhanced by more than two fold as a result of Fc incorporation. Cyclic voltammetry, differential pulse voltammetry and amperometry all demonstrated the excellent response of the Naf/ @entity6 /Fc/GCE biosensor to @entity1 . The sensor system generated a linear response over a range of 500nM to 600 M UA, with a sensitivity and limit of detection of 1.78 A M(-1) and 230nM, respectively. The heterogeneous rate constant (ks) for UA oxidation was much higher for Naf/ @entity6 /Fc/GCE (1.0*10(-4)cms(-1)) than for @entity4 / @entity6 /GCE (8.2*10(-5)cms(-1)). Real samples, i.e. @entity0 blood, were tested for serum UA and the sensor yielded accurate results at a 95% confidence limit.

title: A novel third generation @entity1 biosensor using uricase electro-activated with @entity2 on a @entity5 coated glassy XXXX electrode.

answer: @entity3


abstract: A new @entity1 biosensor was constructed using @entity2 (Fc) induced electro-activated uricase ( @entity6 ) deposited within @entity5 (Naf) on glassy @entity3 electrode (GCE). Electro-activation of @entity6 was successfully achieved by cyclic voltammetry through the electrostatic interaction of Fc with Trp residues within the hydrophobic pockets in @entity6 . The Naf/ @entity6 /Fc composite was characterised by AFM, FTIR and EDX to ensure proper immobilisation. The interaction of Fc with the enzyme was analysed by Trp fluorescence spectroscopy and the a-helicity of the protein was measured by CD spectropolarimetry. The charge transfer resistance (Rct), calculated from electrochemical impedance spectroscopy, for the modified sensor was lowered (1.39k   ) and the enzyme efficiency was enhanced by more than two fold as a result of Fc incorporation. Cyclic voltammetry, differential pulse voltammetry and amperometry all demonstrated the excellent response of the Naf/ @entity6 /Fc/GCE biosensor to @entity1 . The sensor system generated a linear response over a range of 500nM to 600 M UA, with a sensitivity and limit of detection of 1.78 A M(-1) and 230nM, respectively. The heterogeneous rate constant (ks) for UA oxidation was much higher for Naf/ @entity6 /Fc/GCE (1.0*10(-4)cms(-1)) than for @entity4 / @entity6 /GCE (8.2*10(-5)cms(-1)). Real samples, i.e. @entity0 blood, were tested for serum UA and the sensor yielded accurate results at a 95% confidence limit.

title: A novel third generation XXXX biosensor using uricase electro-activated with @entity2 on a @entity5 coated glassy @entity3 electrode.

answer: @entity1


abstract: A new @entity1 biosensor was constructed using @entity2 (Fc) induced electro-activated uricase ( @entity6 ) deposited within @entity5 (Naf) on glassy @entity3 electrode (GCE). Electro-activation of @entity6 was successfully achieved by cyclic voltammetry through the electrostatic interaction of Fc with Trp residues within the hydrophobic pockets in @entity6 . The Naf/ @entity6 /Fc composite was characterised by AFM, FTIR and EDX to ensure proper immobilisation. The interaction of Fc with the enzyme was analysed by Trp fluorescence spectroscopy and the a-helicity of the protein was measured by CD spectropolarimetry. The charge transfer resistance (Rct), calculated from electrochemical impedance spectroscopy, for the modified sensor was lowered (1.39k   ) and the enzyme efficiency was enhanced by more than two fold as a result of Fc incorporation. Cyclic voltammetry, differential pulse voltammetry and amperometry all demonstrated the excellent response of the Naf/ @entity6 /Fc/GCE biosensor to @entity1 . The sensor system generated a linear response over a range of 500nM to 600 M UA, with a sensitivity and limit of detection of 1.78 A M(-1) and 230nM, respectively. The heterogeneous rate constant (ks) for UA oxidation was much higher for Naf/ @entity6 /Fc/GCE (1.0*10(-4)cms(-1)) than for @entity4 / @entity6 /GCE (8.2*10(-5)cms(-1)). Real samples, i.e. @entity0 blood, were tested for serum UA and the sensor yielded accurate results at a 95% confidence limit.

title: A novel third generation @entity1 biosensor using uricase electro-activated with @entity2 on a XXXX coated glassy @entity3 electrode.

answer: @entity5


abstract: @entity5 is a nonsteroidal anti-inflammatory agent with additional antipyretic and analgesic activity. The recommended dosage is 100 to 200 mg twice daily orally or rectally. The pharmacokinetics profile of @entity5 has been studied in @entity0 with a predisposition for altered pharmacokinetics. The pharmacokinetic profile of @entity5 and its hydroxy metabolite was not altered when the drug was administered in a standard regimen (100mg twice daily) to elderly @entity0 aged < 80 years, suggesting that dosage adjustment is not necessary for such @entity0 . In @entity0 aged 7 to 9 years, @entity5 50mg administered in a granular formulation showed a tendency for greater absorption and elimination than that recorded for adults administered @entity5 in tablet form. These results suggest that the pharmacokinetic profile of this paediatric formulation should be assessed in @entity0 aged < 7 years to determine whether their dosage should be adjusted. In @entity0 with moderate @entity3 , the pharmacokinetic profile of @entity5 was not altered even though the terminal elimination half-life of its @entity4 metabolite was greater and this resulted in slight accumulation with multiple dose administration in a standard regimen. This slight effect was not considered to be clinically significant and therefore dosage adjustment for @entity0 with moderate @entity1 appears unnecessary. Administration of @entity5 to @entity0 with severe @entity3 should be avoided until the propensity and significance of @entity6 accumulation is quantified in this @entity0 group. The pharmacokinetic profile of @entity5 has not been determined in @entity0 with @entity2 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effect of age and disease on the pharmacokinetics of XXXX .

answer: @entity5


abstract: @entity5 is a weak complete carcinogen and potent @entity0 promoter. In vivo, @entity5 causes a rapid but transient increase in liver growth, whereas in cultured female hepatocytes it enhances DNA synthesis induced by epidermal growth factor and is thus classified as a comitogen. The objectives of this study were to determine: (a) whether @entity2 also has comitogenic activity; (b) whether the comitogenic effects of @entity3 extend to complete hepatic mitogens other than epidermal growth factor and (c) whether inhibition of hepatocyte DNA synthesis by transforming growth factor-beta can be blocked by @entity2 . Female @entity1 hepatocytes in primary culture were exposed to @entity2 with and without various growth factors, and we determined DNA synthesis by measuring @entity4 incorporation into extracted DNA or by determining the nuclear labeling index by means of autoradiography. The results show that @entity2 , like @entity5 , has comitogenic activity for epidermal growth factor, although it is somewhat less potent. Four complete hepatic mitogens showed different abilities to stimulate DNA synthesis, with hepatocyte growth factor > transforming growth factor-alpha > epidermal growth factor > @entity6 . @entity2 enhanced DNA synthesis occurring in response to all four of these complete hepatic mitogens. This finding suggests that the mechanism of @entity3 comitogenesis may involve effects at a point where the different signal-transduction pathways leading from the growth factors converge. The level of @entity3 -mediated enhancement of DNA synthesis was similar for all four mitogens, ranging from 1.5 to 2.2-fold, depending on the experiment. Furthermore, determination of the nuclear labeling index showed that @entity3 enhancement of DNA synthesis was associated with an increase in the percentage of hepatocytes that responded to the growth factors. Finally, @entity2 did not specifically block the growth-inhibitory effects of transforming growth factor-beta.

title: Comitogenic effects of XXXX on DNA synthesis induced by various growth factors in cultured female @entity1 hepatocytes.

answer: @entity3


abstract: @entity5 is a weak complete carcinogen and potent @entity0 promoter. In vivo, @entity5 causes a rapid but transient increase in liver growth, whereas in cultured female hepatocytes it enhances DNA synthesis induced by epidermal growth factor and is thus classified as a comitogen. The objectives of this study were to determine: (a) whether @entity2 also has comitogenic activity; (b) whether the comitogenic effects of @entity3 extend to complete hepatic mitogens other than epidermal growth factor and (c) whether inhibition of hepatocyte DNA synthesis by transforming growth factor-beta can be blocked by @entity2 . Female @entity1 hepatocytes in primary culture were exposed to @entity2 with and without various growth factors, and we determined DNA synthesis by measuring @entity4 incorporation into extracted DNA or by determining the nuclear labeling index by means of autoradiography. The results show that @entity2 , like @entity5 , has comitogenic activity for epidermal growth factor, although it is somewhat less potent. Four complete hepatic mitogens showed different abilities to stimulate DNA synthesis, with hepatocyte growth factor > transforming growth factor-alpha > epidermal growth factor > @entity6 . @entity2 enhanced DNA synthesis occurring in response to all four of these complete hepatic mitogens. This finding suggests that the mechanism of @entity3 comitogenesis may involve effects at a point where the different signal-transduction pathways leading from the growth factors converge. The level of @entity3 -mediated enhancement of DNA synthesis was similar for all four mitogens, ranging from 1.5 to 2.2-fold, depending on the experiment. Furthermore, determination of the nuclear labeling index showed that @entity3 enhancement of DNA synthesis was associated with an increase in the percentage of hepatocytes that responded to the growth factors. Finally, @entity2 did not specifically block the growth-inhibitory effects of transforming growth factor-beta.

title: Comitogenic effects of @entity3 on DNA synthesis induced by various growth factors in cultured female XXXX hepatocytes.

answer: @entity1


abstract: INTRODUCTION: @entity4 ( @entity4 ) is caused by uninhibited secretion of @entity3 from a @entity2 . Gastrinomas most commonly arise within the wall of the duodenum followed by the pancreas. @entity1 have also been reported in the literature. This is a case of @entity4 where preoperative localization revealed a @entity2 in a solitary portacaval lymph node, presumed to be a primary lymph node @entity2 . PRESENTATION OF CASE: The @entity0 is a 57 year old female diagnosed with @entity4 , suspected of having a primary lymph node @entity2 . The @entity0 underwent an exploratory laparotomy and excision of a portacaval lymph node with a frozen section which was positive for @entity2 . Intraoperative sonography of the pancreas, upper endoscopy with transillumination of the duodenum, and a duodenotomy with bimanual examination of the duodenal wall were also performed. The @entity0 was found to have a 4mm duodenal mass near the pylorus, which was excised. DISCUSSION: Pathology showed that the duodenal mass was primary @entity2 . Serum @entity3 levels taken four months postoperatively were normal and the repeat octreotide scan did not show any evidence of recurrence. CONCLUSION: @entity1 is a diagnosis of exclusion. The duodenum and pancreas must be fully explored to rule out a primary @entity2 that may be occult.

title: XXXX . A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature.

answer: @entity1


abstract: Recently, we reported that @entity9 ( @entity6 ), a natural cofactor for hydroxylases of @entity1 and @entity5 , has a @entity4 -releasing action independent of its cofactor activity. Here we attempted to determine whether 6R-BH4 acts inside the cell or from the outside of the cell by using brain microdialysis in the @entity0 striatum. For this purpose, sepiapterin, and immediate precursor of 6R-BH4 in the salvage pathway, was used to selectively increase the intracellular 6R-BH4 levels. Dialytic perfusion of sepiapterin increased tissue levels of reduced biopterin (mainly 6R-BH4) but not the extracellular levels. Administration of @entity10 increased the extracellular levels of @entity8 ( @entity8 ) (an index of in vivo @entity1 hydroxylase activity) and of @entity3 (DA) (an index of in vivo DA release). Either of the increases was eliminated after pretreatment with a @entity1 hydroxylase inhibitor @entity7 . Administration of 6R-BH4 increased extracellular levels of reduced biopterin. @entity8 , and DA. After pretreatment with @entity7 , the increase in @entity8 levels was abolished, but most of the increase in DA levels persisted. The increase in DA levels also persisted after pretreatment with @entity2 synthase inhibitors. These data demonstrate that 6R-BH4 stimulates DA release directly, independent of its cofactor action for @entity1 hydroxylase and @entity2 synthase, by acting from the outside of neurons.

title: XXXX -releasing action of @entity9 : analysis of its action site using sepiapterin.

answer: @entity3


abstract: Recently, we reported that @entity9 ( @entity6 ), a natural cofactor for hydroxylases of @entity1 and @entity5 , has a @entity4 -releasing action independent of its cofactor activity. Here we attempted to determine whether 6R-BH4 acts inside the cell or from the outside of the cell by using brain microdialysis in the @entity0 striatum. For this purpose, sepiapterin, and immediate precursor of 6R-BH4 in the salvage pathway, was used to selectively increase the intracellular 6R-BH4 levels. Dialytic perfusion of sepiapterin increased tissue levels of reduced biopterin (mainly 6R-BH4) but not the extracellular levels. Administration of @entity10 increased the extracellular levels of @entity8 ( @entity8 ) (an index of in vivo @entity1 hydroxylase activity) and of @entity3 (DA) (an index of in vivo DA release). Either of the increases was eliminated after pretreatment with a @entity1 hydroxylase inhibitor @entity7 . Administration of 6R-BH4 increased extracellular levels of reduced biopterin. @entity8 , and DA. After pretreatment with @entity7 , the increase in @entity8 levels was abolished, but most of the increase in DA levels persisted. The increase in DA levels also persisted after pretreatment with @entity2 synthase inhibitors. These data demonstrate that 6R-BH4 stimulates DA release directly, independent of its cofactor action for @entity1 hydroxylase and @entity2 synthase, by acting from the outside of neurons.

title: @entity3 -releasing action of XXXX : analysis of its action site using sepiapterin.

answer: @entity9


abstract: In previous studies two neurite growth inhibiting protein fractions of 35 and 250 kDa were identified in myelin preparations of the @entity1 CNS. These activities were not found in the myelin of PNS. A monoclonal antibody (mAb IN-1) was raised against the 250 kDa protein fraction and selected for its ability to neutralize the inhibitory effect of CNS myelin and of both isolated protein fractions. IN-1 has been shown both in vitro and in vivo to neutralize the inhibitory effect of differentiated @entity2 . In the present study, the antigens of IN-1 were localized by immunohistochemistry on cryostat sections of the adult @entity1 nervous system. The staining pattern of IN-1 was compared to that of mAbs specific for proteins found in CNS and PNS myelin. These proteins include @entity6 , @entity5 , and @entity7 . IN-1 stained white matter and myelinated fibre tracts in the CNS on sections of fresh frozen tissue fixed with 95% @entity3 : 5% @entity4 (Clark's solution). @entity0 and spinal roots remained unstained. The staining pattern of IN-1 corresponded most closely to that of a mAb against @entity5 , a protein which occurs exclusively in CNS myelin and on differentiated oligodendrocytes.

title: A monoclonal antibody (IN-1) which neutralizes neurite growth inhibitory proteins in the XXXX CNS recognizes antigens localized in CNS myelin.

answer: @entity1


abstract: PURPOSE: To report an unrecognized EEG pattern occurring in @entity0 with @entity7 with @entity4 ( @entity4 ) treated with thiopental and characterized by a high amplitude generalized sharp wave that was induced by isolated or repetitive low frequency photic or tactile stimulation (stimulus-induced generalized @entity6 ). METHODS: Review of clinical and EEG records of 4 @entity0 with stimulus-induced generalized @entity6 identified among @entity0 admitted to an intensive care unit (ICU) of our institution who underwent EEG monitoring between July 2011 and January 2013. RESULTS: Four @entity0 had refractory @entity4 secondary to @entity2 , @entity8 , immunomediated @entity1 , or anti- @entity3 @entity5 . All of them were treated with several antiepileptic drugs and anesthetics, but stimulus-induced generalized @entity6 were only recorded after control of @entity4 with thiopental. The discharges occurred without associated clinical manifestations. Two @entity0 died in the ICU, and two had a favorable outcome. Stimulus-induced generalized @entity6 were not recorded in 240 critically ill @entity0 admitted to the ICU who had an EEG recorded during this period. Twenty-two of them were in @entity4 , and only one was treated with thiopental. CONCLUSIONS: Stimulus-induced generalized @entity6 is an EEG pattern occurring in @entity0 with @entity4 treated with thiopental. The clinical relevance and pathophysiology of stimulus-induced generalized @entity6 remain to be clarified.

title: Stimulus-induced generalized @entity6 : an unrecognized EEG pattern in refractory XXXX .

answer: @entity4


abstract: PURPOSE: To report an unrecognized EEG pattern occurring in @entity0 with @entity7 with @entity4 ( @entity4 ) treated with thiopental and characterized by a high amplitude generalized sharp wave that was induced by isolated or repetitive low frequency photic or tactile stimulation (stimulus-induced generalized @entity6 ). METHODS: Review of clinical and EEG records of 4 @entity0 with stimulus-induced generalized @entity6 identified among @entity0 admitted to an intensive care unit (ICU) of our institution who underwent EEG monitoring between July 2011 and January 2013. RESULTS: Four @entity0 had refractory @entity4 secondary to @entity2 , @entity8 , immunomediated @entity1 , or anti- @entity3 @entity5 . All of them were treated with several antiepileptic drugs and anesthetics, but stimulus-induced generalized @entity6 were only recorded after control of @entity4 with thiopental. The discharges occurred without associated clinical manifestations. Two @entity0 died in the ICU, and two had a favorable outcome. Stimulus-induced generalized @entity6 were not recorded in 240 critically ill @entity0 admitted to the ICU who had an EEG recorded during this period. Twenty-two of them were in @entity4 , and only one was treated with thiopental. CONCLUSIONS: Stimulus-induced generalized @entity6 is an EEG pattern occurring in @entity0 with @entity4 treated with thiopental. The clinical relevance and pathophysiology of stimulus-induced generalized @entity6 remain to be clarified.

title: Stimulus-induced generalized XXXX : an unrecognized EEG pattern in refractory @entity4 .

answer: @entity6


abstract: PURPOSE: @entity3 ( @entity3 ) are a devastating @entity1 of infancy. Analysis of infraslow EEG activity (ISA) has shown potential in the presurgical evaluation of @entity0 with @entity1 and in differentiating between focal and @entity5 . Infraslow EEG activity analysis may provide insights into the pathophysiology of some @entity1 , such as @entity3 . To our knowledge, there are no published reports describing ISA in @entity0 with @entity3 . The purpose of this study was to describe ictal patterns of ISA in @entity0 with @entity3 and to correlate with clinical data. METHODS: EEG recordings of all cases of @entity3 in the past 10 years at the Alberta @entity0 's Hospital were reviewed. Inclusion criteria were a technically adequate video EEG recording that captured at least one @entity4 . For each @entity0 , the first 10 confirmed @entity4 were examined. Spasms were evaluated for changes in ISA, which were either generalized, lateralized, or absent ISA (g-ISA, l-ISA, or n-ISA, respectively). Results were correlated with treatments, clinical course, and information pertinent to likely etiology of the @entity3 . RESULTS: A total of 77% of @entity4 were associated with ISA; 57% with g-ISA, 20% l-ISA, and 21% n-ISA. All @entity0 with exclusively g-ISA showed at least a partial response to initial therapy, while this was the case in 66.7% of those with at least some l-ISA and 50% of those with exclusively n-ISA. Other @entity2 types occurred in 60% of @entity0 with exclusively g-ISA versus 83% with some l-ISA and all @entity0 with exclusively n-ISA. CONCLUSIONS: Ictal ISA was observed in the majority of @entity3 . Trends were observed suggesting that the presence of exclusive g-ISA changes may be a positive prognostic factor in @entity3 .

title: Infraslow EEG changes in infantile XXXX .

answer: @entity4


abstract: The levels of 16 @entity0 ( @entity1 ) were determined in the liver, kidney, gills and muscle tissues of Persian sturgeon (Acipenser persicus; n=16), and @entity6 ( @entity6 ; n=7) collected from coastal waters of the South Caspian Sea from March and April 2011. The distribution and composition pattern of @entity1 in the different tissues of sturgeons, and the effects of lipid content in sturgeon tissues and the @entity2 -water partition coefficient (Kow) of @entity1 congeners on them were analyzed. The levels of total @entity1 in the various tissues of Persian sturgeon and @entity6 ranged from 2.095 to 6.587 and 1.942 to 6.206 gg(-1)dw, respectively. @entity6 showed significantly higher levels of heavy @entity1 (   4-rings) than Persian sturgeon. The analysis has revealed a high degree of differential accumulation of the studied @entity1 in the tissues of the both species. Low molecular weight @entity1 predominated in the sturgeons, accounting for 81.89% of the total @entity1 . Among the sixteen tested @entity1 , @entity5 was the most dominant congener, followed by @entity4 and @entity3 . The @entity1 levels and distribution in the tissues of sturgeons are dependent on both the Kow of @entity1 congeners and the lipid content in these tissues. There was a significant positive relationship (r=0.868, p<0.005) between lipid content and @entity1 levels. The statistically significant negative relationships (p<0.01) were found between log Kow and log-transformed @entity1 levels for muscle tissues of both sturgeon species.

title: Distribution and composition pattern of XXXX in different tissues of sturgeons collected from Iranian coastline of the Caspian Sea.

answer: @entity0


abstract: Infection of @entity0 with verotoxin-producing @entity3 (VTEC) O113:H21 is associated with clinical features comparable to those associated with @entity2 with attaching and effacing VTEC strains including those of serotype O157:H7. We have shown previously that the adhesion phenotype of VTEC O157:H7 is influenced by the presence of a homolog of the chromosomal eaeA (for @entity3 attaching and effacing) gene. In contrast, by colony blot hybridization, VTEC O113:H21 is negative for the eaeA gene. Therefore, the aim of this study was to define the adhesion phenotype of VTEC O113:H21 strain CL-15 to both cultured epithelial cells (HEp-2) and @entity1 intestine in vivo. Under transmission electron microscopy, areas of microvillus effacement were observed in regions directly beneath the organism in @entity2 cells both in vitro and in vivo. However, F-actin adhesion pedestals on the host plasma membrane were absent. Failure of CL-15 to induce polymerization of actin was confirmed by using staining of F-actin with @entity4 -labeled @entity5 . Under indirect immunofluorescence microscopy, @entity2 HEp-2 cells also failed to demonstrate the recruitment of another cytoskeletal element, @entity6 , below foci of bacterial adhesion. In contrast, VTEC O157:H7 @entity2 of HEp-2 cells was associated with increased @entity6 immunofluorescence. These findings suggest that bacterial factors distinct from those of EaeA are necessary for the adhesion phenotype of VTEC O113:H21.

title: Distinct binding properties of eaeA-negative verocytotoxin-producing XXXX of serotype O113:H21.

answer: @entity3


abstract: OBJECTIVE: Social cognition has been shown to be affected in @entity2 , even during euthymia. However, the social cognitive profile of this group of disorders remains to be ascertained, given that such a broad neuropsychological construct has not been systematically examined in bipolar subjects across different tasks. The aim of this study was to quantify the magnitude of @entity0 -control differences for distinct social cognition assessment instruments: the Hinting Task, the Eyes Test, Faux Pas, the Mayer-Salovey-Caruso Emotional Intelligence Test, and emotional labeling using visual stimuli. METHOD: Effect sizes were extracted from studies chosen according to more stringent criteria than previously used in systematic reviews on the topic and pooled by means of meta-analytical procedures. RESULTS: No significant @entity0 -control differences were found for the recognition of three basic emotions (happiness, sadness, and anger). Small but significant effect sizes favoring healthy controls (Hedges*  g<0.5) were noted for emotional intelligence, the Hinting Task, the Eyes Test, and the recognition of fear, disgust, and surprise. A medium effect size (Hedges*  g=0.58) was noted for the Faux Pas Test. LIMITATIONS: The possible effects of other @entity1 on social cognitive performance could not be explored. CONCLUSION: On average, small-to-moderate differences may exist between euthymic @entity2 subjects and healthy controls regarding social cognitive performance, with mental state decoding being more preserved than mental state reasoning. The influence of clinical and neurocognitive variables, which may play an important role in the social cognitive outcomes of these @entity0 , deserves further clarification.

title: An individual task meta-analysis of social cognition in euthymic XXXX .

answer: @entity2


abstract: BACKGROUND: Systemic @entity4 is considered beneficial to @entity3 @entity0 . However, many complications ensue. The aim of this study was to evaluate the effect of a new invasive regional cooling device in @entity5 in a @entity1 model. METHODS: After a pilot study confirming the efficiency of the cooling device, 15 adult male @entity1 , weighing 300-400  g, were randomly assigned into three groups: cooling device applied at 14  C and at 26  C, and a sham group. Focal @entity5 was achieved by electrocauterization of the left middle cerebral artery through craniectomy and temporal occlusion of both common carotid arteries for 3 hours. Within 30 minutes after the end of @entity2 , the cooling device was inserted into the @entity1 brain through a stereotactic frame to provide regional @entity4 for 2 hours. The @entity1 were sacrificed immediately after the 2-hour regional @entity4 . RESULTS: Although @entity6 staining showed smaller @entity5 in both the 26  C and 14  C groups compared to the control group, Fluoro Jade C staining showed no neuroprotective effects in the rostrum cerebral cortex in both groups. However, both @entity6 and Fluoro Jade C staining indicated significant beneficial effects in the caudal cerebral cortex in @entity1 with cooling device applied at 26  C compared to the 14  C and control groups. CONCLUSION: Our findings indicated that the device can effectively achieve regional @entity4 and could be beneficial for @entity0 with @entity5 during the acute phase.

title: Protective effect against focal XXXX in acute phase of a novel invasive device for regional @entity4 .

answer: @entity5


abstract: BACKGROUND: Systemic @entity4 is considered beneficial to @entity3 @entity0 . However, many complications ensue. The aim of this study was to evaluate the effect of a new invasive regional cooling device in @entity5 in a @entity1 model. METHODS: After a pilot study confirming the efficiency of the cooling device, 15 adult male @entity1 , weighing 300-400  g, were randomly assigned into three groups: cooling device applied at 14  C and at 26  C, and a sham group. Focal @entity5 was achieved by electrocauterization of the left middle cerebral artery through craniectomy and temporal occlusion of both common carotid arteries for 3 hours. Within 30 minutes after the end of @entity2 , the cooling device was inserted into the @entity1 brain through a stereotactic frame to provide regional @entity4 for 2 hours. The @entity1 were sacrificed immediately after the 2-hour regional @entity4 . RESULTS: Although @entity6 staining showed smaller @entity5 in both the 26  C and 14  C groups compared to the control group, Fluoro Jade C staining showed no neuroprotective effects in the rostrum cerebral cortex in both groups. However, both @entity6 and Fluoro Jade C staining indicated significant beneficial effects in the caudal cerebral cortex in @entity1 with cooling device applied at 26  C compared to the 14  C and control groups. CONCLUSION: Our findings indicated that the device can effectively achieve regional @entity4 and could be beneficial for @entity0 with @entity5 during the acute phase.

title: Protective effect against focal @entity5 in acute phase of a novel invasive device for regional XXXX .

answer: @entity4


abstract: INTRODUCTION: Medication-induced @entity1 are a major concern in drug development as a multitude of prescription drugs alter sleep patterns, often negatively. Polysomnography is used in clinical diagnostics but is also applicable to animal models. Rodent sleep architecture (nocturnal) differs from larger diurnal mammals, including @entity0 , increasing the translational potential of non-rodent species to the clinic. This study aimed to characterize the response to pharmacological agents known to affect sleep structure and EEG activity in a non- @entity0 primate ( @entity5 ) using telemetry-based polysomnography. METHODS: Animals were instrumented with telemetry transmitters for continuous electroencephalogram (EEG), electro-oculogram (EOG) and electromyogram (EMG) monitoring combined with video. EEG, EMG and EOG were monitored for 12 to 24h to establish baseline values, followed by administration of pharmacological agents (saline, @entity2 , @entity3 or @entity6 ). RESULTS: @entity4 (0.3 and 1mg/kg, by oral administration (PO)) significantly reduced total sleep time, including the duration of both non-rapid eye movement [NREM] sleep and REM sleep. It also decreased EEG activity in low frequencies (i.e., 4-6Hz) during wakefulness. @entity3 (2mg/kg, PO) did not significantly alter sleep duration, but importantly reduced EEG activity in low frequencies (approximately 2-12Hz) during wakefulness, NREM and REM sleep. Finally, @entity6 (10 and 30mg/kg, PO) decreased both NREM and REM sleep duration. In addition, spectral analysis revealed important decreases in low frequency activity (i.e., 1-8Hz) during wakefulness with a parallel increase in high frequency activity (i.e., 20-50Hz) during NREM sleep. DISCUSSION: As these observations are similar to previously reported pharmacological effects in @entity0 , results support that EEG, EOG and EMG monitoring by telemetry in @entity5 represents a useful non-clinical model to investigate and quantify drug-induced @entity1 .

title: Reprint of "Effects of @entity4 , XXXX and @entity6 on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in @entity5 ".

answer: @entity3


abstract: INTRODUCTION: Medication-induced @entity1 are a major concern in drug development as a multitude of prescription drugs alter sleep patterns, often negatively. Polysomnography is used in clinical diagnostics but is also applicable to animal models. Rodent sleep architecture (nocturnal) differs from larger diurnal mammals, including @entity0 , increasing the translational potential of non-rodent species to the clinic. This study aimed to characterize the response to pharmacological agents known to affect sleep structure and EEG activity in a non- @entity0 primate ( @entity5 ) using telemetry-based polysomnography. METHODS: Animals were instrumented with telemetry transmitters for continuous electroencephalogram (EEG), electro-oculogram (EOG) and electromyogram (EMG) monitoring combined with video. EEG, EMG and EOG were monitored for 12 to 24h to establish baseline values, followed by administration of pharmacological agents (saline, @entity2 , @entity3 or @entity6 ). RESULTS: @entity4 (0.3 and 1mg/kg, by oral administration (PO)) significantly reduced total sleep time, including the duration of both non-rapid eye movement [NREM] sleep and REM sleep. It also decreased EEG activity in low frequencies (i.e., 4-6Hz) during wakefulness. @entity3 (2mg/kg, PO) did not significantly alter sleep duration, but importantly reduced EEG activity in low frequencies (approximately 2-12Hz) during wakefulness, NREM and REM sleep. Finally, @entity6 (10 and 30mg/kg, PO) decreased both NREM and REM sleep duration. In addition, spectral analysis revealed important decreases in low frequency activity (i.e., 1-8Hz) during wakefulness with a parallel increase in high frequency activity (i.e., 20-50Hz) during NREM sleep. DISCUSSION: As these observations are similar to previously reported pharmacological effects in @entity0 , results support that EEG, EOG and EMG monitoring by telemetry in @entity5 represents a useful non-clinical model to investigate and quantify drug-induced @entity1 .

title: Reprint of "Effects of XXXX , @entity3 and @entity6 on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in @entity5 ".

answer: @entity4


abstract: INTRODUCTION: Medication-induced @entity1 are a major concern in drug development as a multitude of prescription drugs alter sleep patterns, often negatively. Polysomnography is used in clinical diagnostics but is also applicable to animal models. Rodent sleep architecture (nocturnal) differs from larger diurnal mammals, including @entity0 , increasing the translational potential of non-rodent species to the clinic. This study aimed to characterize the response to pharmacological agents known to affect sleep structure and EEG activity in a non- @entity0 primate ( @entity5 ) using telemetry-based polysomnography. METHODS: Animals were instrumented with telemetry transmitters for continuous electroencephalogram (EEG), electro-oculogram (EOG) and electromyogram (EMG) monitoring combined with video. EEG, EMG and EOG were monitored for 12 to 24h to establish baseline values, followed by administration of pharmacological agents (saline, @entity2 , @entity3 or @entity6 ). RESULTS: @entity4 (0.3 and 1mg/kg, by oral administration (PO)) significantly reduced total sleep time, including the duration of both non-rapid eye movement [NREM] sleep and REM sleep. It also decreased EEG activity in low frequencies (i.e., 4-6Hz) during wakefulness. @entity3 (2mg/kg, PO) did not significantly alter sleep duration, but importantly reduced EEG activity in low frequencies (approximately 2-12Hz) during wakefulness, NREM and REM sleep. Finally, @entity6 (10 and 30mg/kg, PO) decreased both NREM and REM sleep duration. In addition, spectral analysis revealed important decreases in low frequency activity (i.e., 1-8Hz) during wakefulness with a parallel increase in high frequency activity (i.e., 20-50Hz) during NREM sleep. DISCUSSION: As these observations are similar to previously reported pharmacological effects in @entity0 , results support that EEG, EOG and EMG monitoring by telemetry in @entity5 represents a useful non-clinical model to investigate and quantify drug-induced @entity1 .

title: Reprint of "Effects of @entity4 , @entity3 and @entity6 on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in XXXX ".

answer: @entity5


abstract: INTRODUCTION: Medication-induced @entity1 are a major concern in drug development as a multitude of prescription drugs alter sleep patterns, often negatively. Polysomnography is used in clinical diagnostics but is also applicable to animal models. Rodent sleep architecture (nocturnal) differs from larger diurnal mammals, including @entity0 , increasing the translational potential of non-rodent species to the clinic. This study aimed to characterize the response to pharmacological agents known to affect sleep structure and EEG activity in a non- @entity0 primate ( @entity5 ) using telemetry-based polysomnography. METHODS: Animals were instrumented with telemetry transmitters for continuous electroencephalogram (EEG), electro-oculogram (EOG) and electromyogram (EMG) monitoring combined with video. EEG, EMG and EOG were monitored for 12 to 24h to establish baseline values, followed by administration of pharmacological agents (saline, @entity2 , @entity3 or @entity6 ). RESULTS: @entity4 (0.3 and 1mg/kg, by oral administration (PO)) significantly reduced total sleep time, including the duration of both non-rapid eye movement [NREM] sleep and REM sleep. It also decreased EEG activity in low frequencies (i.e., 4-6Hz) during wakefulness. @entity3 (2mg/kg, PO) did not significantly alter sleep duration, but importantly reduced EEG activity in low frequencies (approximately 2-12Hz) during wakefulness, NREM and REM sleep. Finally, @entity6 (10 and 30mg/kg, PO) decreased both NREM and REM sleep duration. In addition, spectral analysis revealed important decreases in low frequency activity (i.e., 1-8Hz) during wakefulness with a parallel increase in high frequency activity (i.e., 20-50Hz) during NREM sleep. DISCUSSION: As these observations are similar to previously reported pharmacological effects in @entity0 , results support that EEG, EOG and EMG monitoring by telemetry in @entity5 represents a useful non-clinical model to investigate and quantify drug-induced @entity1 .

title: Reprint of "Effects of @entity4 , @entity3 and XXXX on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in @entity5 ".

answer: @entity6


abstract: OBJECTIVE: To assess a program in which @entity2 ( @entity2 ) provided @entity0 with self-sampling devices to detect high-risk @entity3 ). METHODS: In a cross-sectional study, 13 @entity2 visited homes in a rural area in Haiti's Central Plateau to recruit premenopausal @entity0 aged 30-50years between July 2009 and April 2010. Eligible @entity0 had not undergone a cervical smear in the previous 3years. @entity0 learned about cervical @entity1 and self-sampling for HPV testing before using a self-sampler in private. They then completed a questionnaire. @entity2 later returned to provide results and advice about follow-up care. RESULTS: @entity2 enrolled 493 @entity0 . Among the 485 @entity0 for whom questionnaires were received, 468 (96.5%) were comfortable using the self-sampler and 484 (99.8%) stated they would recommend it to others. Among 426 analyzed samples, 54 (12.7%) were positive for high-risk HPV, of whom 46 (85.2%) received follow-up care and 17 (31.5%) had precursor lesions and were treated. CONCLUSION: Using a CHW-led intervention, @entity0 at high risk for developing cervical @entity1 were identified and navigated to preventive care. Therefore, pairing @entity2 with HPV self-sampling is a promising strategy to combat cervical @entity1 and similar settings.

title: Pairing XXXX with HPV self-sampling for cervical @entity1 prevention in rural Haiti.

answer: @entity2


abstract: OBJECTIVE: To assess a program in which @entity2 ( @entity2 ) provided @entity0 with self-sampling devices to detect high-risk @entity3 ). METHODS: In a cross-sectional study, 13 @entity2 visited homes in a rural area in Haiti's Central Plateau to recruit premenopausal @entity0 aged 30-50years between July 2009 and April 2010. Eligible @entity0 had not undergone a cervical smear in the previous 3years. @entity0 learned about cervical @entity1 and self-sampling for HPV testing before using a self-sampler in private. They then completed a questionnaire. @entity2 later returned to provide results and advice about follow-up care. RESULTS: @entity2 enrolled 493 @entity0 . Among the 485 @entity0 for whom questionnaires were received, 468 (96.5%) were comfortable using the self-sampler and 484 (99.8%) stated they would recommend it to others. Among 426 analyzed samples, 54 (12.7%) were positive for high-risk HPV, of whom 46 (85.2%) received follow-up care and 17 (31.5%) had precursor lesions and were treated. CONCLUSION: Using a CHW-led intervention, @entity0 at high risk for developing cervical @entity1 were identified and navigated to preventive care. Therefore, pairing @entity2 with HPV self-sampling is a promising strategy to combat cervical @entity1 and similar settings.

title: Pairing @entity2 with HPV self-sampling for cervical XXXX prevention in rural Haiti.

answer: @entity1